Effects of nicotine nasal spray on atherogenic and thrombogenic factors during smoking cessation

J Intern Med. 1999 Jul;246(1):61-6. doi: 10.1046/j.1365-2796.1999.00506.x.

Abstract

Objectives: To investigate changes in cardiovascular risk factor parameters when stopping smoking and to identify any impact of nicotine nasal spray on these factors.

Design and subjects: In a placebo-controlled, double-blind 3-month prospective study, nicotine nasal spray (NNS) or a placebo was given to 157 subjects attending a smoking cessation programme. Blood samples from 46 subjects who remained abstinent for 3 months were analysed. Nasal spray use was given on an ad libitum basis.

Results: The haemoglobin (Hb) decreased from 149.0 to 143.2 g L(-1) (P<0.001). The haematocrit (Hct) decreased from 44.6 to 42.4% (P<0.001). The mean corpuscular volume (MCV) decreased from 93.4 to 92.3 fl (P<0.001). The mean corpuscular haemoglobin concentration (MCHC) increased from 333.9 to 338.1 g L(-1) (P = 0.029). The white blood cell count (WBC) decreased from 8.4 to 6.6x10(9) L(-1) (P<0.001). The total cholesterol decreased from 5.92 to 5.65 mmol L(-1) (P = 0.015). The high-density lipoprotein cholesterol (HDL) increased from 1.29 to 1.44 mmol L(-1) (P = 0.48) and low-density lipoprotein cholesterol (LDL) decreased from 4.00 to 3.54 mmol L(-1) (P = 0.004). The HDL/LDL ratio increased from 0.36 to 0.46 (P = 0.011).

Conclusion: Stopping smoking resulted in positive effects on cardiovascular risk factors. Nicotine treatment for as long as 3 months did not have any significant effect on these 'stopping smoking changes'. In smoking cessation, nicotine substitution up to 3 months seems to be safe.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Administration, Intranasal
  • Adult
  • Aged
  • Arteriosclerosis / etiology*
  • Cardiovascular Diseases / etiology
  • Cholesterol / blood
  • Double-Blind Method
  • Erythrocyte Indices
  • Female
  • Fibrinogen / metabolism
  • Hematocrit
  • Hemoglobins / metabolism
  • Humans
  • Leukocyte Count
  • Male
  • Middle Aged
  • Nicotine / pharmacology*
  • Nicotinic Agonists / pharmacology*
  • Platelet Count
  • Prospective Studies
  • Risk Factors
  • Smoking Cessation*
  • Thrombosis / etiology*

Substances

  • Hemoglobins
  • Nicotinic Agonists
  • Nicotine
  • Fibrinogen
  • Cholesterol